Notice of Results Archives - Advanced Medical Solutions https://admedsol.com/message-type/notice-of-results/ Mon, 01 Sep 2025 07:00:12 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://admedsol.com/wp-content/uploads/2026/02/cropped-Web-Icon-32x32.png Notice of Results Archives - Advanced Medical Solutions https://admedsol.com/message-type/notice-of-results/ 32 32 Notice of Interim Results https://admedsol.com/regulatory-news-announcements/7792069/ Mon, 01 Sep 2025 07:00:12 +0000 https://admedsol1stg.wpenginepowered.com/regulatory-news-announcements/7792069/ RNS Number : 3098X Advanced Medical Solutions Grp PLC 01 September 2025   1 September 2025   Advanced Medical Solutions Group plc (“AMS” or the “Group”)   Notice of Interim Results     Winsford, UK: Advanced Medical Solutions Group plc (AIM:AMS), a world-leading specialist in tissue-healing technologies, will announce its interim results for the six […]

The post Notice of Interim Results appeared first on Advanced Medical Solutions.

]]>

RNS Number : 3098X
Advanced Medical Solutions Grp PLC
01 September 2025
 

1 September 2025

 

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Notice of Interim Results

 

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM:AMS), a world-leading specialist in tissue-healing technologies, will announce its interim results for the six months ended 30 June 2025 on Wednesday 17 September 2025.

A briefing for analysts will be held at 10:45am BST on the day of the results. For further information, please contact AMS@optimumcomms.com.

 

At 2:30pm BST the same day, a presentation by Chris Meredith, Chief Executive Officer and Eddie Johnson, Chief Financial Officer will be available via Investor Meet Company.

 

The presentation is open to all existing and potential shareholders and will also be published on the Company’s website following its release.

 

Investors can sign up to Investor Meet Company for free and add Advanced Medical Solutions plc via: https://www.investormeetcompany.com/advanced-medical-solutions-group-plc/register-investor   

 

– End –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations



 

Optimum Strategic Communications

Tel: +44 (0) 20 4566 8543

Mary Clark / Nick Bastin / Isabelle Abdou

AMS@optimumcomms.com



Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Gary Clarence / David Anderson

 

 

Berenberg (Joint Broker)    

Tel: +44 (0)20 3207 7800

Toby Flaux / Detlir Elezi / Yasmina Benchekroun


 

About Advanced Medical Solutions Group plc – see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

 

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,600 employees. For more information, please see www.admedsol.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 
 

NOREKLFLEVLFBBK

The post Notice of Interim Results appeared first on Advanced Medical Solutions.

]]> Notice of Interim Results https://admedsol.com/regulatory-news-announcements/5747548/ Thu, 29 Aug 2024 07:00:13 +0000 https://admedsol1stg.wpenginepowered.com/?post_type=rns-post&p=8553 RNS Number : 0523C Advanced Medical Solutions Grp PLC 29 August 2024   29 August 2024 Advanced Medical Solutions Group plc (“AMS” or the “Group”) Notice of Interim Results   Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, will announce its interim results for the six months ended […]

The post Notice of Interim Results appeared first on Advanced Medical Solutions.

]]>

RNS Number : 0523C
Advanced Medical Solutions Grp PLC
29 August 2024
 

29 August 2024

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

Notice of Interim Results

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, will announce its interim results for the six months ended 30 June 2024 on Wednesday 18 September 2024.

 

A briefing for analysts will be held at 10am BST on the day of the results. For further information, please contact AMS@consilium-comms.com.

 

 

– End –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

 

 

 

ICR Consilium

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Lucy Featherstone

AMS@consilium-comms.com

 

 

Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Gary Clarence / David Anderson

 

 

HSBC Bank plc (Broker)

Tel: 44 (0) 20 7991 8888

Joe Weaving / Stephanie Cornish

 

 

 

 

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

 

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,500 employees. For more information, please see www.admedsol.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 
 

NORQVLFLZVLBBBD

The post Notice of Interim Results appeared first on Advanced Medical Solutions.

]]> Notice of Interim Results https://admedsol.com/regulatory-news-announcements/notice-of-interim-results-8/ Thu, 10 Aug 2023 07:00:06 +0000 https://admedsol1stg.wpenginepowered.com/investor-relations/regulatory-news-announcements/no-rid-4936/ The post Notice of Interim Results appeared first on Advanced Medical Solutions.

]]>
RNS Number : 0235L
Advanced Medical Solutions Grp PLC
31 August 2023
Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

Notice of Interim Results

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, will announce its interim results for the six months ended 30 June 2023 on Wednesday 20 September 2023.

 

A briefing for analysts will be held at 10am BST on the day of the results. For further information, please contact AMS@consilium-comms.com.

 

– End –

 

The post Notice of Interim Results appeared first on Advanced Medical Solutions.

]]> Notice of Results https://admedsol.com/regulatory-news-announcements/notice-of-results-7/ Tue, 14 Feb 2023 07:01:01 +0000 https://admedsol1stg.wpenginepowered.com/investor-relations/regulatory-news-announcements/no-rid-4881/ RNS Number : 7883P Advanced Medical Solutions Grp PLC 14 February 2023   14 February 2023   Advanced Medical Solutions Group plc (“AMS” or the “Group”)   Notice of Preliminary Results   Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, will announce its preliminary results for the twelve […]

The post Notice of Results appeared first on Advanced Medical Solutions.

]]>

RNS Number : 7883P
Advanced Medical Solutions Grp PLC
14 February 2023
 

14 February 2023

 

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Notice of Preliminary Results

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, will announce its preliminary results for the twelve months ended 31 December 2022 on Wednesday 15 March 2023.

 

A briefing for analysts will be held at 10am GMT on the day of the results. For further information, please contact AMS@consilium-comms.com.

 

– End –

 

 

 

For further information, please contact:

 

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations



 

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

 



Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence/ David Anderson

 


HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish


 

 

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made four acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies, Raleigh, a UK leading coater and converter of materials predominately for woundcare and bio-diagnostics products and AFS Medical, an Austrian a specialist surgical business with a focus on minimally invasive procedures.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 
 

NORGPUBWPUPWGBW

The post Notice of Results appeared first on Advanced Medical Solutions.

]]> Notice of Interim Results https://admedsol.com/regulatory-news-announcements/notice-of-interim-results-7/ Wed, 17 Aug 2022 07:00:08 +0000 https://admedsol1stg.wpenginepowered.com/investor-relations/regulatory-news-announcements/no-rid-4808/ The post Notice of Interim Results appeared first on Advanced Medical Solutions.

]]>
RNS Number : 2421W
Advanced Medical Solutions Grp PLC
17 August 202217 August 2022

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Notice of Interim Results

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, will announce its interim results for the six months ended 30 June 2022 on Wednesday, 14 September 2022.

A briefing for analysts will be held at 10am GMT on the day of the results. For further information, please contact AMS@consilium-comms.com.

 

– End –

The post Notice of Interim Results appeared first on Advanced Medical Solutions.

]]> Notice of Results https://admedsol.com/regulatory-news-announcements/notice-of-results-6/ Mon, 07 Mar 2022 07:00:11 +0000 https://admedsol1stg.wpenginepowered.com/investor-relations/regulatory-news-announcements/no-rid-4716/ The post Notice of Results appeared first on Advanced Medical Solutions.

]]>
RNS Number : 7792D
Advanced Medical Solutions Grp PLC
07 March 2022
 

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Notice of Preliminary Results

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, will announce its preliminary results for the twelve months ended 31 December 2021 on Wednesday, 16 March 2022.

 

A briefing for analysts will be held at 10am GMT on the day of the results at 85 Gresham Street, EC2V 7NQ. For further information, please contact AMS@consilium-comms.com.

The post Notice of Results appeared first on Advanced Medical Solutions.

]]> Notice of Interim Results https://admedsol.com/regulatory-news-announcements/notice-of-interim-results-6/ Tue, 17 Aug 2021 07:00:05 +0000 https://admedsol.wpengine.com/investor-relations/regulatory-news-announcements/no-rid-4570/ The post Notice of Interim Results appeared first on Advanced Medical Solutions.

]]>

RNS Number : 8181I
Advanced Medical Solutions Grp PLC
17 August 2021

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Notice of Interim Results

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, is expected to announce its interim results for the six months ended 30 June 2021 on Wednesday, 15 September 2021.

 

An analyst briefing will be held at 10.30am BST on the day of the results. For more information please contact AMS@consilium-comms.com.

 

– End –

The post Notice of Interim Results appeared first on Advanced Medical Solutions.

]]> Notice of Results https://admedsol.com/regulatory-news-announcements/notice-of-results-5/ Thu, 04 Mar 2021 07:00:10 +0000 https://admedsol.wpengine.com/investor-relations/regulatory-news-announcements/no-rid-4409/ RNS Number : 1035R Advanced Medical Solutions Grp PLC 04 March 2021   04 March 2021   Advanced Medical Solutions Group plc (“AMS” or the “Group”)   Notice of Preliminary Results     Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, will announce its preliminary results […]

The post Notice of Results appeared first on Advanced Medical Solutions.

]]>

RNS Number : 1035R
Advanced Medical Solutions Grp PLC
04 March 2021
 

04 March 2021

 

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Notice of Preliminary Results

 

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, will announce its preliminary results for the twelve months ended 31 December 2020 on Wednesday, 17 March 2021.

 

A virtual briefing for analysts will be held at 9:30am GMT on the day of the results. For more information on the conference call, please contact AMS@consilium-comms.com.

 

 

– End –

 

 

 

 

For further information, please contact:

 

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer




Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Olivia Manser




Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Daniel Adams / Patrick Robb / Gary Clarence


 

 

About Advanced Medical Solutions Group plc 

 

AMS is a world-leading developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBandFix8®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a leading coater and converter of materials predominately for woundcare and bio-diagnostics products based in the UK.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has approximately 700 employees. For more information, please see www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 
 

NORFZGGFMFVGMZZ

The post Notice of Results appeared first on Advanced Medical Solutions.

]]> Notice of Results https://admedsol.com/regulatory-news-announcements/notice-of-results-4/ Thu, 03 Sep 2020 07:00:07 +0000 https://admedsol.wpengine.com/investor-relations/regulatory-news-announcements/no-rid-4269/ RNS Number : 8820X Advanced Medical Solutions Grp PLC 03 September 2020   03 September 2020   Advanced Medical Solutions Group plc (“AMS” or the “Group”)   Notice of Interim Results     Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, will announce its interim results […]

The post Notice of Results appeared first on Advanced Medical Solutions.

]]>

RNS Number : 8820X
Advanced Medical Solutions Grp PLC
03 September 2020
 

03 September 2020

 

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Notice of Interim Results

 

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, will announce its interim results for the six months ended 30 June 2020 on Wednesday, 16 September 2020.

 

A virtual briefing for analysts will be held at 9:30am BST on the day of the results. For more information on the conference call, please contact AMS@consilium-comms.com.

 

– End –

 

 

 

 

For further information, please contact:

 

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer




Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Olivia Manser




Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Daniel Adams / Patrick Robb / Gary Clarence


 

 

About Advanced Medical Solutions Group plc 

 

AMS is a world-leading developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBandFix8®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has approximately 700 employees. For more information, please see www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 
 

NORDZGGLMZLGGZZ

The post Notice of Results appeared first on Advanced Medical Solutions.

]]> Notice of Interim Results https://admedsol.com/regulatory-news-announcements/notice-of-interim-results-5/ Thu, 08 Aug 2019 07:00:20 +0000 https://admedsol.wpengine.com/investor-relations/regulatory-news-announcements/no-rid-3795/ RNS Number : 3230I Advanced Medical Solutions Grp PLC 08 August 2019   8 August 2019   Advanced Medical Solutions Group plc (“AMS”, the “Company” or the “Group”)   Notice of Interim Results   Winsford, UK, 8 August 2019: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, will […]

The post Notice of Interim Results appeared first on Advanced Medical Solutions.

]]>
RNS Number : 3230I
Advanced Medical Solutions Grp PLC
08 August 2019
 

8 August 2019

 

Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

Notice of Interim Results

 

Winsford, UK, 8 August 2019: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, will announce its interim results for the six months ended 30 June 2019 on Wednesday 11 September 2019.

 

A briefing for analysts will be held at 09.30am BST on the day of results in the Dome Room, 1 Cornhill, London, EC3V 3ND. Please contact Consilium Strategic Communications for further details.

 

– End –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

 

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer


 



 

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

 

Mary-Jane Elliott / Matthew Neal / Nicholas Brown / Olivia Manser

AMS@consilium-comms.com

 



 

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

 

Daniel Adams / Gary Clarence / Patrick Robb


 

 

 

 

 

About Advanced Medical Solutions Group plc – see www.admedsol.com

 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound care markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of products that include tissue adhesives, sutures, haemostats, internal fixation devices, silver alginates, alginates and foams, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and ActivHeal® as well as supplying under white label.

 

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 77 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 650 employees. For more information please see www.admedsol.com.

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 

END

 
 

NORBDLLBKVFLBBF

The post Notice of Interim Results appeared first on Advanced Medical Solutions.

]]>